source
- Marengo's bispecific antibody invikafusp alfa shows tumor shrinkage in 8 cancer types in Phase 2Marengo Therapeutics presented Phase 2 data for its bispecific antibody invikafusp alfa at the European Society for Medical Oncology meeting in Madrid. The study, part of the Start-001 first‑in‑hum…
- Tango Therapeutics reports 82% tumor response in combo trial for advanced pancreatic cancerTango Therapeutics and Revolution Medicines presented data showing that their experimental combination therapy produced tumor responses in 82% of patients with a specific form of advanced pancreati…